Stephen B. Willingham

9.4k citations

43 papers · 5.5k indexed · 3 hit papers · h-index 23

Immunology top 0.5%
Molecular Biology top 2%
Oncology top 2%
Physiology top 5%
Surgery top 10%

Co-authors: Jenny P.‐Y. Ting Dan T. Bergstralh Irving L. Weissman Joseph A. Duncan Fabio Re Kipp Weiskopf Ravindra Majeti Max T. Huang
Topics: Adenosine and Purinergic Signaling (13 papers)Phagocytosis and Immune Regulation (11 papers)Inflammasome and immune disorders (9 papers)
Cited by: Immunology Physiology Oncology
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United States Germany India

In The Last Decade

Stephen B. Willingham

41 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

2010 594 citations Mark P. Chao, Ash A. Alizadeh et al. profile →
Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP3

2008 510 citations Stephen B. Willingham, Jenny P.‐Y. Ting et al. The Journal of Immunology profile →
Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

2013 506 citations Jens-Peter Volkmer, Stephen B. Willingham et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Stephen B. Willingham

Since Specialization

Citations

This map shows the geographic impact of Stephen B. Willingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen B. Willingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen B. Willingham more than expected).

Fields of papers citing papers by Stephen B. Willingham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen B. Willingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen B. Willingham. The network helps show where Stephen B. Willingham may publish in the future.

Co-authorship network of co-authors of Stephen B. Willingham

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen B. Willingham. A scholar is included among the top collaborators of Stephen B. Willingham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen B. Willingham. Stephen B. Willingham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance 2021 ·Proceedings of the National Academy of Sciences ·(unknown),Allison Banuelos,Dongdong Feng,(unknown),Kevin S. Kao,Kelly M. McKenna,Stephen B. Willingham,Po Y. Ho,Benyamin Rosental,Michal Caspi Tal,Tal Raveh,Jens-Peter Volkmer,Mark D. Pegram,Irving L. Weissman	95
2	Targeting the A2AR in cancer; early lessons from the clinic 2020 ·Current Opinion in Pharmacology ·Stephen B. Willingham,Andrew Hotson,Richard A. Miller	37
3	Neisseria gonorrhoeae Activates the Proteinase Cathepsin B to Mediate the Signaling Activities of the NLRP3 and ASC-Containing Inflammasome 2020 ·UNC Libraries ·Dan T. Bergstralh,Stephen B. Willingham,(unknown),Christopher Thomas,Gary A. Jarvis,Joseph A. Duncan,Brian P. O’Connor,P. Frederick Sparling,Jenny P.‐Y. Ting,(unknown)	4
4	A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models 2018 ·Cancer Immunology Research ·Stephen B. Willingham,Po Y. Ho,Andrew Hotson,Craig Hill,Emily Piccione,Jessica Hsieh,Liang Liu,Joseph J. Buggy,Ian McCaffery,Richard A. Miller	162
5	A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer 2017 ·Nature ·Paola Betancur,Brian J. Abraham,Ying Ying Yiu,Stephen B. Willingham,(unknown),Mark A. Zarnegar,Angera H. Kuo,Kelly M. McKenna,Yoko Kojima,Nicholas J. Leeper,Po Y. Ho,Phung Gip,Tomek Swigut,Richard I. Sherwood,Michael F. Clarke,George Somlo,Richard A. Young,Irving L. Weissman	1
6	Abstract 5593: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies 2017 ·Cancer Research ·Stephen B. Willingham,Andrew Hotson,Po Y. Ho,(unknown),Walter Kim,Erik Yusko,Sharon Benzeno,Ginna G. Laport,Richard A. Miller,Ian McCaffery	1
7	A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer 2017 ·Nature Communications ·Paola Betancur,Brian J. Abraham,Ying Ying Yiu,Stephen B. Willingham,(unknown),Mark A. Zarnegar,Angera H. Kuo,Kelly M. McKenna,Yoko Kojima,Nicholas J. Leeper,Po Y. Ho,Phung Gip,Tomek Swigut,Richard I. Sherwood,Michael F. Clarke,George Somlo,Richard A. Young,Irving L. Weissman	178
8	Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1 2016 ·Annals of Oncology ·Stephen B. Willingham,Po Y. Ho,Robert D. Leone,(unknown),Jonathan D. Powell,Ian McCaffery,Richard A. Miller	2
9	Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers 2016 ·Annals of Oncology ·Ian McCaffery,Ginna G. Laport,Andrew Hotson,Stephen B. Willingham,Amita Patnaik,M. Beeram,Rebecca L. Miller	6
10	Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential 2015 ·PLoS ONE ·Jie Liu,Lijuan Wang,Feifei Zhao,Serena Tseng,Cyndhavi Narayanan,(unknown),Stephen B. Willingham,Maureen Howard,Susan Prohaska,Jens Volkmer,Mark P. Chao,Irving L. Weissman,Ravindra Majeti	381
11	Learning from Host-Defense Peptides: Cationic, Amphipathic Peptoids with Potent Anticancer Activity 2014 ·PLoS ONE ·Wei Huang,Jiwon Seo,Stephen B. Willingham,Ann M. Czyzewski,Mark L. Gonzalgo,Irving L. Weissman,Annelise E. Barron	68
12	Three differentiation states risk-stratify bladder cancer into distinct subtypes 2012 ·Proceedings of the National Academy of Sciences ·Jens-Peter Volkmer,Debashis Sahoo,Robert Chin,Philip Levy Ho,Chad Tang,Antonina V. Kurtova,Stephen B. Willingham,Senthil Pazhanisamy,Humberto Contreras-Trujillo,Theresa A. Storm,Yair Lotan,Andrew H. Beck,Benjamin I. Chung,Ash A. Alizadeh,Guilherme Godoy,Seth P. Lerner,Matt van de Rijn,Linda D. Shortliffe,Irving L. Weissman,Keith Syson Chan	187
13	Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells 2012 ·Leukemia ·Donghee Kim,Jian Wang,Stephen B. Willingham,(unknown),Gerlinde Wernig,Irving L. Weissman	180
14	Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma 2012 ·Proceedings of the National Academy of Sciences ·Badreddin Edris,Kipp Weiskopf,Anne Kathrin Volkmer,Jens-Peter Volkmer,Stephen B. Willingham,Humberto Contreras-Trujillo,Jie Liu,Ravindra Majeti,Robert B. West,Jonathan A. Fletcher,Andrew H. Beck,Irving L. Weissman,Matt van de Rijn	211
15	Neisseria gonorrhoeae Activates the Proteinase Cathepsin B to Mediate the Signaling Activities of the NLRP3 and ASC-Containing Inflammasome 2009 ·The Journal of Immunology ·Joseph A. Duncan,Xi Gao,Max T. Huang,Brian P. O’Connor,Christopher Thomas,Stephen B. Willingham,Dan T. Bergstralh,Gary A. Jarvis,P. Frederick Sparling,Jenny P.‐Y. Ting	213
16	Critical Role of Apoptotic Speck Protein Containing a Caspase Recruitment Domain (ASC) and NLRP3 in Causing Necrosis and ASC Speck Formation Induced by Porphyromonas gingivalis in Human Cells 2009 ·The Journal of Immunology ·Max T. Huang,Debra J. Taxman,Elizabeth Holley-Guthrie,Chris B. Moore,Stephen B. Willingham,Victoria J. Madden,(unknown),(unknown),Roland Arnold,Brian P. O’Connor,Jenny Pan-Yun Ting	63
17	Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP3breakdown → 2008 ·The Journal of Immunology ·(unknown),Stephen B. Willingham,Jenny P.‐Y. Ting,Fabio Re	510
18	NLRs at the intersection of cell death and immunity 2008 ·Nature reviews. Immunology ·Jenny P.‐Y. Ting,Stephen B. Willingham,Dan T. Bergstralh	286
19	Microbial Pathogen-Induced Necrotic Cell Death Mediated by the Inflammasome Components CIAS1/Cryopyrin/NLRP3 and ASC 2007 ·Cell Host & Microbe ·Stephen B. Willingham,Dan T. Bergstralh,William O’Connor,Amy C. Morrison,Debra J. Taxman,Joseph A. Duncan,Shoshana Barnoy,Malabi M. Venkatesan,Richard A. Flavell,Mohanish Deshmukh,Hal M. Hoffman,Jenny P.‐Y. Ting	234
20	Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein 2003 ·Science ·Stephen B. Willingham,Tiago F. Outeiro,Michael J. DeVit,Susan Lindquist,Paul J. Muchowski	328

About Stephen B. Willingham

Stephen B. Willingham is a scholar working on Physiology, Immunology and Oncology, having authored 43 papers that have together received 5.5k indexed citations. Recurring topics across this work include Adenosine and Purinergic Signaling (13 papers), Phagocytosis and Immune Regulation (11 papers) and Inflammasome and immune disorders (9 papers). The work is most often cited by research in Immunology (3.1k citations), Physiology (238 citations) and Oncology (1.1k citations). Stephen B. Willingham has collaborated with scholars based in United States, Germany and India. Frequent co-authors include Jenny P.‐Y. Ting, Dan T. Bergstralh, Irving L. Weissman, Joseph A. Duncan, Fabio Re, Kipp Weiskopf, Ravindra Majeti, Max T. Huang, Mark P. Chao and Jens Volkmer. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact